TumorDiagnostik & Therapie, Table of Contents TumorDiagnostik & Therapie 2016; 37(03): 128-131DOI: 10.1055/s-0042-102691 Schwerpunkt: Immuntherapie Georg Thieme Verlag KG Stuttgart · New York Übersicht – Möglichkeiten und Grenzen der Therapie mit Checkpoint-Inhibitoren B. Kühnemuth , D. Anz Recommend Article Abstract Buy Article Full Text References Literatur 1 Kobold S, Duewell P, Schnurr M et al. Immunotherapy in Tumors. Dtsch Arztebl Int 2015; 112: 809-815 2 Anz D, Rapp M, Eiber S et al. Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression. Cancer Res 2015; 75: 4483-4493 3 Hamid O, Schmidt H, Nissan A et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011; 9: 204 4 Ji RR, Chasalow SD, Wang L et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012; 61: 1019-1031 5 Snyder A, Makarov V, Merghoub T et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371: 2189-2199 6 Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373: 123-135 7 Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454 8 Meng X, Huang Z, Teng F et al. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev 2015; 41: 868-876 9 Wolchok JD, Hoos A, OʼDay S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420 10 Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer 2009; 45: 228-247 11 Weber J, Hamid O, Amin A et al. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun 2013; 13: 7 12 Ribas A, Hodi FS, Callahan M et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368: 1365-1366 13 Rini BI, Stein M, Shannon P et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 2011; 117: 758-767 14 Gibney GT, Kudchadkar RR, DeConti RC et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 2015; 21: 712-720
